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Abstract
The EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (CEF) was
requested to deliver a scientiﬁc opinion on the implications for human health of the ﬂavouring substance
4-amino-5-(3-(isopropylamino)-2,2-dimethyl-3-oxopropoxy)-2-methylquinoline-3-carboxylic acid [FL-no:
16.130], in the Flavouring Group Evaluation 407 (FGE.407), according to Regulation (EC) No 1331/2008
of the European Parliament and of the Council. The substance has not been reported to occur in natural
source materials of botanical or animal origin. It is intended to be used as both the parent compound and
its hemisulfate monohydrate salt as a ﬂavouring substance with modifying properties in speciﬁc
categories of food. The chronic dietary exposure to the substance estimated using the added portions
exposure technique (APET), is calculated to be 882 lg/person per day for a 60-kg adult and 547 lg/person
per day for a 15-kg 3-year-old child. There is no concern with respect to genotoxicity. A 90-day dietary
administration study in rats showed no adverse effects for doses up to 100 mg/kg body weight (bw)
per day, providing an adequate margin of safety. Developmental toxicity was not observed in a study
with rats at the dose levels up to 1,000 mg/kg bw per day. The Panel concluded that [FL-no: 16.130]
and its hemisulfate monohydrate salt are not expected to be of safety concern at the estimated levels
of dietary exposure calculated using the APET approach. This conclusion applies only to the use of the
substance as a ﬂavour modiﬁer as requested and when used at the levels as speciﬁed for foods from
different food categories.
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Summary
Following a request from the European Commission, the European Food Safety Authority (EFSA)
Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (CEF Panel) was asked to
deliver a scientiﬁc opinion on the implications for human health of a chemically deﬁned ﬂavouring
substance used in or on foodstuffs in the Member States. In particular, EFSA was requested to
evaluate 4-amino-5-(3-(isopropylamino)-2,2-dimethyl-3-oxopropoxy)-2-methylquinoline-3-carboxylic
acid [FL-no: 16.130], allocated in the Flavouring Group Evaluation 407 (FGE.407), using the Procedure
as referred to in Regulation (EC) No 1334/2008 of the European Parliament and of the Council.
Despite sharing some structural elements with other ﬂavouring substances (e.g. methylquinolines or
anthranilates), these are not sufﬁciently structurally related to the candidate substance. Consequently,
the Panel decided to assess this substance on its own.
4-Amino-5-(3-(isopropylamino)-2,2-dimethyl-3-oxopropoxy)-2-methylquinoline-3-carboxylic acid [FL-
no: 16.130] is chemically synthesised and has not been reported to occur in natural source materials
of botanical or animal origin.
Speciﬁcations
The Panel noted that both the parent compound [FL-no: 16.130] and its hemisulfate monohydrate
salt are intended to be added to foodstuffs.
Speciﬁcations including complete purity criteria and identity for the materials of commerce for both
[FL-no: 16.130] and its salt, have been provided and considered adequate. The candidate substance
does not possess chiral centres or double bonds that would give rise to optical or geometrical isomers.
The information provided on the manufacturing process, the composition and the stability of the
ﬂavouring substance and its hemisulfate monohydrate salt were considered sufﬁcient.
Use and exposure
4-Amino-5-(3-(isopropylamino)-2,2-dimethyl-3-oxopropoxy)-2-methylquinoline-3-carboxylic acid and
its sulfate salt, [FL-no: 16.130], are intended to be used as ﬂavouring substances with modifying
properties1 in speciﬁc food categories.
The chronic dietary exposure to the candidate substance has been estimated using the added
portions exposure technique (APET). It is calculated to be 882 lg/person per day (14.7 lg/kg body
weight (bw) per day for a 60-kg adult) and 547 lg/person per day (36.4 lg/kg bw per day for a 15-kg
3-year-old child).
The highest acute intake of the candidate substance results from the consumption of non-alcoholic
beverages containing 7 mg/kg of the candidate substance consumed by a 60-kg adult and a 15-kg
3-year-old child. This results in an intake of 6.3 mg/person per day (or 105 lg/kg bw per day for a
60-kg adult), and in an intake of 4.0 mg/person per day (or 265 lg/kg bw per day for a 15-kg 3-year-old
child).
Absorption, distribution, metabolism and elimination
Absorption, distribution, metabolism and elimination (ADME) studies in rats available for [FL-no:
16.130] and its sulfate salt indicate that both forms are poorly absorbed after oral administration and
no signiﬁcant metabolism is expected in the gastrointestinal tract.
Genotoxicity
[FL-no: 16.130] contains a structural alert for genotoxicity in the form of an amino-substituted
aromatic ring. However, the substance gave negative results when tested in a bacterial gene mutation
assay and micronucleus assay in vitro. Based on these results, the Panel concluded that there is no
concern with respect to genotoxicity for the candidate substance [FL-no: 16.130]. Therefore, the
safety of the substance was evaluated according to the Procedure for the evaluation of chemically
deﬁned ﬂavouring substances.
1 Regulation (EC) No 1334/2008 of the European Parliament and of the Council of 16 December 2008 on ﬂavourings and certain
food ingredients with ﬂavouring properties for use in and on foods and amending Council Regulation (EEC) No 1601/91,
Regulations (EC) No 2232/96 and (EC) No 110/2008 and Directive 2000/13/EC. Ofﬁcial Journal of the European Union, L 354,
34–50.
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Systemic toxicity
A 90-day systemic toxicity study in the rat has been performed. Dietary administration of [FL-no:
16.130] to CD rats for 13 weeks at doses up to 100 mg/kg bw per day was well tolerated. Based on
the ﬁndings in this study, the no-observed-adverse-effect-level (NOAEL) was considered to be 100 mg/kg
bw per day, the highest dose tested, in both sexes.
Developmental toxicity
In a developmental toxicity study, rats were administered oral doses of 250–1,000 mg/kg bw per
day of the candidate substance. There were no statistically signiﬁcant differences between the treated
and control groups. Therefore, there is no concern for developmental toxicity of [FL-no: 16.130] in rats
at dose levels up to 1,000 mg/kg bw per day, the highest dose tested.
Safety assessment for acute exposure
Estimates of maximum acute dietary exposure indicate that this would be about 265 lg/kg bw for a
3-year-old child, which is higher than the acute exposure estimate for an adult (105 lg/kg bw per
day). From these data, a margin of exposure of 380 for children can be calculated, which indicates no
concern for acute effects, taking into account that the NOAEL was derived from a 90-day toxicity
study. In addition, no toxicity was observed at dose levels up to 1,000 mg/kg bw per day in a
developmental toxicity study with an exposure period of 14 days.
Safety assessment for long-term exposure
Since no clear structural/metabolic similarity of the candidate substance to ﬂavouring substances in
an existing FGE was identiﬁed, the Panel proceeded with the individual evaluation of the candidate
substance [FL-no: 16.130], according to the EFSA Guidance (EFSA, 2010).
Based on its chemical structure, the substance has been assigned to Cramer class III. The results
of studies on metabolism and pharmacokinetics do not allow to conclude that its metabolites are
innocuous. Accordingly, the candidate substance is evaluated via the B-side of the Procedure scheme.
Based on the comparison of APET with the Cramer class III threshold, a 90-day study and a
developmental toxicity study were required and carried out for this substance. Adequate margins of
safety of 6,800 for adults and 2,700 for 3-year-old children have been calculated on the basis of the
exposure estimates calculated and the NOAEL from the 90-day toxicity study.
Overall, the Panel concluded that using the NOAEL obtained from a 90-day dietary study in rats,
there is no safety concern for [FL-no: 16.130], when used as a ﬂavouring substance with modifying
properties at the estimated level of dietary exposure calculated using the APET approach and based on
the use levels as speciﬁed in Appendix B.
Flavouring Group Evaluation 407
www.efsa.europa.eu/efsajournal 4 EFSA Journal 2017;15(1):4660
Table of contents
Abstract.................................................................................................................................................. 1
Summary................................................................................................................................................ 3
1. Introduction.............................................................................................................................. 6
1.1. Background and Terms of Reference as provided by the European Commission ............................. 6
1.1.1. Terms of Reference ................................................................................................................... 6
1.2. Interpretation of the Terms of Reference..................................................................................... 6
2. Data and methodologies ............................................................................................................ 6
3. Assessment............................................................................................................................... 7
3.1. Identity of the substance ........................................................................................................... 7
3.2. Organoleptic characteristics........................................................................................................ 7
3.3. Existing authorisations and evaluations ....................................................................................... 7
3.4. Speciﬁcations ............................................................................................................................ 7
3.4.1. Information on the conﬁguration of the ﬂavouring substance ....................................................... 7
3.4.2. Manufacturing process............................................................................................................... 7
3.4.3. Stability and decomposition products .......................................................................................... 8
3.4.3.1. Interaction with food components .............................................................................................. 9
3.4.4. Particle size............................................................................................................................... 9
3.4.5. Conclusion on speciﬁcations ....................................................................................................... 9
3.5. Structural/metabolic similarity to substances in an existing FGE .................................................... 11
3.6. Exposure assessment ................................................................................................................ 11
3.6.1. Concentration in processed and non-processed foods from natural occurrence............................... 11
3.6.2. Non-food sources of exposure.................................................................................................... 11
3.6.3. Chronic dietary exposure ........................................................................................................... 11
3.6.4. Acute dietary exposure .............................................................................................................. 11
3.6.5. Cumulative dietary exposure ...................................................................................................... 12
3.7. Genotoxicity.............................................................................................................................. 12
3.8. Absorption, distribution, metabolism and elimination .................................................................... 12
3.9. Toxicity data ............................................................................................................................. 13
3.9.1. 90-day dietary systemic toxicity study in rats............................................................................... 13
3.9.2. Developmental toxicity study in rats............................................................................................ 13
3.10. Exposure compared to TTC ........................................................................................................ 13
3.11. Procedure for the safety assessment........................................................................................... 14
3.11.1. Safety assessment for acute exposure ........................................................................................ 14
3.11.2. Safety assessment for long-term exposure .................................................................................. 14
3.11.2.1. Procedure steps ........................................................................................................................ 14
3.11.2.2. Step 1 ...................................................................................................................................... 14
3.11.2.3. Step 2 ...................................................................................................................................... 14
3.11.2.4. Step B3 .................................................................................................................................... 14
3.11.2.5. Step B4 .................................................................................................................................... 15
3.12. Margins of safety....................................................................................................................... 15
4. Conclusion ................................................................................................................................ 15
Documentation provided to EFSA ............................................................................................................. 17
References.............................................................................................................................................. 17
Abbreviations .......................................................................................................................................... 18
Appendix A – Production process and decomposition products.................................................................... 20
Appendix B – Use levels and exposure calculations .................................................................................... 24
Appendix C – Genotoxicity ....................................................................................................................... 31
Appendix D – Absorption, distribution, metabolism and elimination ............................................................. 35
Appendix E – Toxicity............................................................................................................................... 37
Appendix F – Procedure for the evaluation of a new ﬂavouring substance ................................................... 41
Flavouring Group Evaluation 407
www.efsa.europa.eu/efsajournal 5 EFSA Journal 2017;15(1):4660
1. Introduction
1.1. Background and Terms of Reference as provided by the European
Commission
The use of ﬂavourings in food is regulated under Regulation (EC) No 1334/20081 of the European
Parliament and Council of 16 December 2008 on ﬂavourings and certain food ingredients with the
ﬂavouring properties for use in and on foods. On the basis of Article 9(a) of this Regulation, an
evaluation and approval are required for ﬂavouring substances.
Regulation (EC) No 1331/20082 applies for the evaluation and approval of new ﬂavouring
substances.
The applicant has submitted an application for authorisation as a new ﬂavouring substance of the
substance: 4-amino-5-(3-(isopropylamino)-2,2-dimethyl-3-oxopropoxy)-2-methylquinoline-3-carboxylic
acid – S9632.
In order for the Commission to be able to consider its inclusion in the Union list of ﬂavourings and
source materials (Annex I of Regulation (EC) No 1334/2008), the European Food Safety Authority
(EFSA) should carry out a safety assessment of this substance.
1.1.1. Terms of Reference
The European Commission requests EFSA to carry out a safety assessment on: 4-amino-5-(3-
(isopropylamino)-2,2-dimethyl-3-oxopropoxy)-2-methylquinoline-3-carboxylic acid – S9632 [FL-no: 16.130]
as a new ﬂavouring substance in accordance with Regulation (EC) No 1331/2008 establishing a common
authorisation procedure for food additives, food enzymes and food ﬂavourings.
1.2. Interpretation of the Terms of Reference
The present scientiﬁc opinion FGE.407 covers the safety assessment of the 4-amino-5-(3-
(isopropylamino)-2,2-dimethyl-3-oxopropoxy)-2-methylquinoline-3-carboxylic acid [FL-no: 16.130]. This
substance will be evaluated as a ﬂavouring substance with modifying properties3 (Regulation (EC)
No 1334/2008). The Panel noted that the substance is intended to be used as parent compound and
hemisulfate monohydrate salt. The Union List4 would also allow the use of the hemisulfate
monohydrate salt under the condition that the parent compound is not of concern.
2. Data and methodologies
The present evaluation is based on data on 4-amino-5-(3-(isopropylamino)-2,2-dimethyl-3-
oxopropoxy)-2-methylquinoline-3-carboxylic acid – [FL-no: 16.130] and its hemisulfate monohydrate
salt provided by the applicant in a dossier submitted in support of its application for authorisation as a
new ﬂavouring substance. The dossier submitted contained data generated for both the candidate
substance and hemisulfate monohydrate salt. The proposed dietary intake of the candidate substance
has been calculated by the applicant based on the use and use levels for a wide range of food and
beverage categories (see Appendix B). Based on these use levels, the Panel has calculated the intakes
in adults and children that were subsequently used in the assessment.
The safety assessment of 4-amino-5-(3-(isopropylamino)-2,2-dimethyl-3-oxopropoxy)-2-methylquinoline-
3-carboxylic acid is carried out by EFSA in accordance with the procedure as lined out in the EFSA
scientiﬁc opinion ‘Guidance on the data required for the risk assessment of ﬂavourings to be used in or
on foods’ (EFSA, 2010) and the technical report of EFSA ‘Proposed template to be used in drafting
scientiﬁc opinions on ﬂavouring substances (explanatory notes for guidance included)’ (EFSA, 2012).
A more thorough explanation on the methodology is given in Appendix F.
2 Regulation (EC) No 1331/2008 of the European Parliament and of the Council of 16 December 2008 establishing a common
authorisation procedure for food additives, food enzymes and food ﬂavourings. OJ L 354, 31.12.2008, p. 1–6.
3 https://ec.europa.eu/food/sites/food/files/safety/docs/fs_food-improvement-agents_flavourings-guidance_modifying_properties.
pdf
4 See Note 1, Section 2, Part A of Annex I of Regulation (EC) No 1334/2008.
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3. Assessment
3.1. Identity of the substance
The candidate substance has been allocated the FLAVIS number (FL-no) 16.130. The name of the
ﬂavouring substance is 4-amino-5-(3-(isopropylamino)-2,2-dimethyl-3-oxopropoxy)-2-methylquinoline-
3-carboxylic acid. According to the application, both the hemisulfate monohydrate salt and the parent
compound are intended to be added to foodstuffs.
3.2. Organoleptic characteristics
The candidate substance imparts a neutral metallic lingering odour. [FL-no: 16.130] is intended to
be used as a substance with ﬂavour-modifying properties.
3.3. Existing authorisations and evaluations
In November 2014, [FL-no: 16.130] was allocated the status ‘Generally Regarded As Safe’ (GRAS)
by the Flavour and Extract Manufactures Associations (FEMAs) expert Panel (FEMA no 4774).
The candidate substance [FL-no: 16.130] and its hemisulfate monohydrate salt (JECFA No 2204.1)
were evaluated as ﬂavouring substances by JECFA in 2014 at the 79th session (JECFA, 2014). The
Committee concluded that ‘on the basis of all of the available evidence, 4-amino-5-(3-(isopropylamino)-
2,2-dimethyl-3-oxopropoxy)- 2-methylquinoline-3-carboxylic acid and its hemisulfate monohydrate salt
would not pose a safety concern at current estimated dietary exposures’ (JECFA, 2014).
3.4. Speciﬁcations
The speciﬁcations of the ﬂavouring substance and its hemisulfate monohydrate are summarised in
Table 1.
3.4.1. Information on the conﬁguration of the ﬂavouring substance
The candidate substance [FL-no: 16.130] does not possess chiral centres and does not have
geometrical or optical isomers.
3.4.2. Manufacturing process
The compound was chemically synthesised from isopropylamine, 3-hydroxy-2,2-dimethylpropanoic
acid, 2-amino-6-ﬂuorobenzonitrile and methylacetoacetate. The process is schematically outlined in
Figure 1.
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3.4.3. Stability and decomposition products
The candidate substance is stable in aqueous solution at 40°C at pH 2.8, 4.0 and 7.1 for a period of
4 weeks. The dry compound as well as the sodium, phosphate and sulfate salts are stable at 100°C up
to 24 h. At 175°C, thermal degradation may take place. The only decomposition product detected
(designated S9379) was formed by decarboxylation and has been fully characterised (for assessment
of its genotoxicity, see Section 3.7) (Figure 2).
Other trials on use in food product prototypes, such as ready-to-drink coffee beverage (100°C for
8 min), cake (177°C for 30 min) and cookie (204°C for 8 min), showed full stability as measured by
the recovery upon quantitative analysis. For hard candies (149°C for 30 min), a lower recovery of 87%
was reported for the parent substance. The Panel considered this relatively low recovery as an
analytical artefact since for the sulfate salt a recovery of 104% was reported. In addition, no increase
in the formation of breakdown products was observed.
For more details on the studies on stability and decomposition products, see Appendix A.
Figure 1: Production process of [FL-no: 16.130] and its sulphate salt
[FL-no: 16.130] (X=CO2H)
S9379 (X=H)
Figure 2: [FL-no: 16.130] and the decomposition product formed by decarboxylation
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3.4.3.1. Interaction with food components
Trials in which the stability of the candidate substance has been measured in different aqueous
media as would be encountered in food and beverage preparations did not indicate any chemical
interaction with other food components. Tasting trials conducted with the candidate substance in
butterscotch pudding and tropical punch-ﬂavoured beverage did not indicate off-notes, loss of
modifying properties or any other signs of interaction with the components of these foods.
3.4.4. Particle size5
The mean particle size of two batches of the compound measured by laser beam ‘Sympatec HELOS
H0415 RODOS’ was 63 and 81 lm (Senomyx, 2016). The substance is not to be considered as a
nanomaterial, as deﬁned by Commission Recommendation 2011/696/EU. The Panel noted that the
applicant indicated that the compound will not be used in formulations other than solutions.
3.4.5. Conclusion on speciﬁcations
The Panel considered the speciﬁcations provided for both the ﬂavouring compound itself [FL-no:
16.130] and for its hemisulfate monohydrate salt, as well as the data on stability of [FL-no: 16.130]
and its hemisulfate monohydrate as dry compounds, in solution and in the course of the production of
different relevant model products, as sufﬁcient.
5 Commission Recommendation 2011/696/EU of 18 October 2011 on the deﬁnition of nanomaterials. Ofﬁcial Journal of the
European Union L257/38-40 on 20.10.2010 (https://ec.europa.eu/research/industrial_technologies/pdf/policy/commission-
recommendation-on-the-definition-of-nanomater-18102011_en.pdf)
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3.5. Structural/metabolic similarity to substances in an existing FGE
Despite sharing some structural elements with other ﬂavouring substances (e.g. methylquinolines or
anthranilates), these are not sufﬁciently structurally related to the candidate substance. Consequently,
the Panel decided to assess this substance on its own.
3.6. Exposure assessment
All data necessary for the calculation exposure estimates (i.e. normal and maximum occurrence
levels for reﬁned subcategories of foods and beverages) are reported in Appendix B.
3.6.1. Concentration in processed and non-processed foods from natural
occurrence
The candidate substance is chemically synthesised and is not expected to occur naturally in food.
According to the applicant, there are no reports of its detection in processed foods. Based on the
chemical structure of the candidate substance, its formation during food processing is not anticipated.
3.6.2. Non-food sources of exposure
No sources of exposure are known to exist from non-food sources.
3.6.3. Chronic dietary exposure
The exposure assessment to be used in the Procedure for the safety evaluation of the candidate
substance is the chronic added portions exposure technique (APET) estimate (EFSA, 2010). The
chronic APET has been calculated for adults and children (see Table 2), and these values, expressed
per kg body weight (bw), will be used in the Procedure (see Appendix B).
Although the substance is not intended to be used in food categories speciﬁcally intended for
infants and toddlers, these could still be exposed through consumption of foods from the general food
categories, which may contain the substance. However, at present, there is no generally accepted
methodology to estimate exposure in these age groups resulting from consumption of foods from the
general categories. Exposure of infants and toddlers is currently under consideration by EFSA.
3.6.4. Acute dietary exposure
The calculation was based on the maximum use levels and large portion size, i.e. three times
standard portion size (see Appendix B).
Although the substance is not intended to be used in food categories speciﬁcally intended for
infants and toddlers, these could still be exposed through consumption of foods from the general food
categories, which may contain the substance. However, at present, there is no generally accepted
methodology to estimate exposure in these age groups resulting from consumption of foods from the
general categories (Table 3).
Table 2: APET – Chronic dietary exposure
Chronic APET
Added(a)
(lg/kg bw per day)
Other dietary sources(b)
(lg/kg bw per day)
Combined(c) (lg/kg bw
per day)
Use level Normal Maximum Average Maximum Normal Maximum
Adults(d) 14.7 n.a. 0 n.a. 14.7 n.a.
Children(e) 36.4 n.a. 0 n.a. 36.4 n.a.
APET: added portions exposure technique; bw: body weight; n.a. not applicable: the chronic APET calculation is based on the
combined normal occurrence level.
(a): APET added is calculated on the basis of the amount of ﬂavour added to a speciﬁc food category.
(b): APET other dietary sources is calculated based on the natural occurrence of the ﬂavour in a speciﬁed food category.
(c): APET combined is calculated based on the combined amount of added ﬂavour and naturally occurring ﬂavour in a speciﬁed
food category.
(d): For the adult APET calculation, a 60-kg person is considered representative.
(e): For the child APET calculation, a 3-year-old child with a 15 kg bw is considered representative.
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3.6.5. Cumulative dietary exposure
Not applicable.
3.7. Genotoxicity
The candidate substance [FL-no: 16.130] contains an aminoquinoline structural entity that is
considered to be a structural alert for genotoxicity. The candidate substance was tested for
genotoxicity in vitro and in vivo in accordance with the OECD Test Guidelines 471, 473, 474 and 487
(OECD 1997a,b,c, 2014).
Parent compound as well as its sodium salt and S9379 (a decomposition product formed by
decarboxylation of [FL-no: 16.130]) did not induce gene mutations in bacterial gene mutation assays in
the presence or absence of metabolic activation, using the plate incorporation or pre-incubation
methods (BioReliance, 2011; Nucro-Technics, 2011a; WIL Research, 2012c).
The sodium salt of [FL-no: 16.130] did not induce chromosomal aberrations in cultured peripheral
human lymphocytes in the presence or absence of metabolic activation (Nucro-Technics, 2011b).
The sulfate salt of [FL-no: 16.130] was negative for the induction of micronuclei in vitro in cultured
human peripheral lymphocytes in the presence and absence of the exogenous metabolic activation
system (BioReliance, 2016).
An in vivo bone marrow micronucleus test in mice did not show any induction of micronuclei by the
test article [FL-no: 16.130]. The lack of cytotoxicity in the bone marrow cells does not allow a
conclusion as whether the test substance or a metabolite reached the bone marrow. Therefore, the
result of this study (Nucro-Technics, 2011c) was considered of limited relevance.
The toxicokinetic study in rats shows that the candidate substance is poorly absorbed and rapidly
eliminated after oral administration. Considering the low systemic exposure, the in vivo micronucleus
assay in bone marrow is not considered an appropriate test to investigate the genotoxicity of this
substance.
Based on the above mentioned considerations and as there was no indication of genotoxicity in a
bacterial gene mutation test and in an in vitro mammalian cell micronucleus test, recommended as the
basic test battery by the EFSA Scientiﬁc Committee (EFSA Scientiﬁc Committee, 2011), the
Panel considered that there is no concern with respect to genotoxicity for the candidate substance.
For full details, see Appendix C.
3.8. Absorption, distribution, metabolism and elimination
A study was performed to determine the toxicokinetic parameters and oral bioavailability of the
candidate substance by either a single intravenous administration or up to 7 days of oral dosing
(gavage) in male and female Sprague–Dawley rats (Senomyx, 2011a).
The candidate substance was poorly bioavailable by the oral route (0.5–1.2% of the dose). It is
rapidly eliminated after either intravenous (T1/2 < 0.27 h) or oral administration (T1/2 < 1.2 h).
Systemic exposure to the candidate substance was roughly proportional with dose and was not
signiﬁcantly different between male and female rats on day 7 vs day 1 of dosing. No signiﬁcant
accumulation of the candidate substance was found in plasma after repeated dosing for seven
consecutive days.
Table 3: APET – Acute dietary exposure
Acute APET
Added(a)
(lg/kg bw per day)
Other dietary sources(b)
(lg/kg bw per day)
Combined(c)
(lg/kg bw per day)
Use level Normal Maximum Average Maximum Normal Maximum
Adults(d) n.a. 105 n.a. 0 n.a. 105
Children(e) n.a. 265 n.a. 0 n.a. 265
APET: added portions exposure technique; bw: body weight; n.a. not applicable: the acute APET calculation is based on the
combined maximum occurrence level.
(a): APET added is calculated on the basis of the amount of ﬂavour added to a speciﬁc food category.
(b): APET other dietary sources is calculated based on the natural occurrence of the ﬂavour in a speciﬁed food category.
(c): APET combined is calculated based on the combined amount of added ﬂavour and naturally occurring ﬂavour in a speciﬁed
food category.
(d): For the adult APET calculation, a 60-kg person is considered representative.
(e): For the child APET calculation, a 3-year-old child with a 15 kg bw is considered representative.
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Toxicokinetic studies during dietary administration for 90 days conﬁrmed the 7 day study ﬁndings.
The bioavailability of the sulfate in the rat after oral dosing was shown to be equivalent to the
parent substance.
Qualitative metabolic proﬁling study of the candidate substance using rat and human hepatic
microsomes showed that the candidate substance was not metabolised during the 60-min incubation
period (PharmOptima, 2011).
The poor bioavailability of [FL-no: 16.130] is also supported by an excretion study conducted with
[FL-no: 16.130] in male and female Sprague–Dawley rats (Senomyx, 2013).
For full details, see Appendix D.
3.9. Toxicity data
A non-good laboratory practice (GLP) 28-day study evaluated the potential toxicity of the candidate
substance. The candidate substance was administered in the diet of three groups of ﬁve male and ﬁve
female CD®[Crl:CD®(SD)] rats at the intended dose levels of 10, 30 and 100 mg/kg bw per day. The
actual average dose levels were within 5% of the intended dose levels based on feed consumption and
measured body weights and concentrations in the feed. Based on a no-observed-adverse-effect-level
(NOAEL) of 100 mg/kg bw per day, the doses for the 90-day study were selected (MPI, 2011a).
3.9.1. 90-day dietary systemic toxicity study in rats
In a 90-day study conducted in compliance with the US Food and Drug Administration Toxicological
Principles for the Safety of Food Ingredients (similar to the OECD Guideline 408) (MPI, 2011b), the
candidate substance was administered in the diet of four groups of twenty male and twenty female
CD®[Crl:CD®(SD)] rats at the intended dose levels of 0 (control), 30, 60 and 100 mg/kg bw per day.
The vehicle or diet containing test article was available ad libitum for 13 weeks. The actual average
dose levels were within 5% of the intended dose levels based on feed consumption and measured
body weights and concentrations in the feed. There were no test article-related effects noted for any
parameter examined. There were no macroscopic or microscopic ﬁndings or toxicologically signiﬁcant
organ weight changes noted at any dose level. As a result, the NOAEL following 13 weeks of dietary
administration was 100 mg/kg per day, the highest dose level tested, in male and female rats.
3.9.2. Developmental toxicity study in rats
A dose-range study for the developmental toxicity has been performed in rats. Based on the results
of this study, the dosage levels of 250, 500 and 1,000 mg/kg bw per day were selected for a deﬁnitive
embryo/fetal development study of the candidate substance administered orally by gavage to inbred
Crl:CD(SD) rats.
A developmental toxicity study was conducted in accordance with the OECD Test Guideline 414
(OECD, 2001), the US FDA Redbook 2000 (Toxicological Principles for the Safety Assessment of Food
Ingredients, as updated) and the Guidelines for Reproduction and Development Studies, January 2001
(WIL Research, 2012b).
Based on the lack of test article-related effects at any dosage level, a dosage level of 1,000 mg/kg
bw per day, the highest dosage level evaluated, was considered to be the NOAEL for maternal toxicity
and embryo/fetal development effects when the candidate substance was administered orally by
gavage to inbred Crl:CD(SD) rats.
The results of the toxicity studies are reported in Appendix E.
3.10. Exposure compared to TTC
By comparison of the APET exposure estimate with the threshold of toxicological concern (TTC, or
in short threshold of concern) and TTC 9 10 (Table 4), it follows from the Procedure (see Appendix F)
that for the evaluation of the candidate ﬂavouring substance the results of a 90-day oral toxicity study
and a developmental toxicity study are necessary (see Appendix F). These studies have been
submitted by the applicant.
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3.11. Procedure for the safety assessment
The Procedure ﬁgure is reported in Appendix F.
Based on the genotoxicity data available, the Panel concluded that for the candidate substance
[FL-no: 16.130] there is no concern with respect to genotoxicity.
3.11.1. Safety assessment for acute exposure
Estimates of maximum acute dietary exposure indicate that this would be about 0.3 mg/kg bw for
a 3-year-old child. The doses of 100 mg/kg bw per day (NOAEL) are well tolerated in rats without
adverse effects. From these data, a margin of exposure of 380 for children can be calculated, which
indicates no concern for acute effects, taking into account that the NOAEL was derived from a 90-day
toxicity study. In a developmental toxicity study with an exposure period of 14 days, no overt maternal
toxicity was observed at a dose levels up to 1,000 mg/kg bw per day, which supports this conclusion.
3.11.2. Safety assessment for long-term exposure
For [FL-no: 16.130], as there is no clear structural/metabolic similarity to other ﬂavouring
substances evaluated in an existing FGE, the Panel decided to assess this substance through the
Procedure for the evaluation of individual ﬂavouring substances (EFSA, 2010) see Appendix F.
3.11.2.1. Procedure steps
Does the candidate substance give rise to concern with respect to genotoxicity?
The candidate substance [FL-no: 16.130] is not considered to be of concern with respect to
genotoxicity (see Section 3.7).
3.11.2.2. Step 1
On the basis of its chemical structure, the candidate substance [FL-no: 16.130] is classiﬁed in
structure class III (Cramer et al., 1978). The TTC for a structural class III substance is 90 lg/person
per day.
3.11.2.3. Step 2
Are there data available to demonstrate that the metabolites can be considered innocuous?
The toxicokinetic and metabolism studies carried out on the candidate substance show that
metabolism only takes place to a very minor degree. It cannot be concluded that the candidate or the
metabolites are innocuous and accordingly the substance proceeds via the B-side of the Procedure.
3.11.2.4. Step B3
Does the dietary exposure exceed the respective Cramer class threshold?
Based on the APET calculation, the chronic exposure to the candidate substance is 882 lg/adult
person per day and 547 lg/child per day.
There are no contributions from structurally related ﬂavouring substances to these values.
The chronic APET for both adults and children exceeds the threshold of 90 lg/person per day and
accordingly the candidate substance proceeds to step B4.
Table 4: Summary table on calculated chronic APET and threshold of concern
FL-no
Structural
class
Add APET Add APET(a)
Threshold of
concern
Threshold of
concern 3 10
16.130
lg/kg bw per
day
lg/person per day
Adult(b) III 14.7 882 90 900
Child(c) 36.4 547
FL-no: FLAVIS no; APET: added portions exposure technique; bw: body weight.
(a): The APET ﬁgure to be used in the Procedure is based on exposure per person per day.
(b): For the adult APET calculation, a 60-kg person is considered representative.
(c): For the child APET calculation, a 3-year-old child with a 15 kg bw is considered representative.
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3.11.2.5. Step B4
Does the dietary exposure exceed the respective Cramer class threshold 9 10?
The daily exposure based on the chronic APET is located between the threshold and 10 times the
threshold (see Table 4). Following the Procedure (see Appendix F), a 90-day study and a
developmental study are required to ﬁnalise the safety evaluation of the candidate substance. Both a
90-day study and developmental study have been performed with the candidate substance and these
studies provide NOAELs of 100 and 1,000 mg/kg bw per day, respectively (see Section 3.9).
3.12. Margins of safety
The NOAEL of the 90-day oral toxicity study (100 mg/kg bw per day) was considered in the risk
assessment of the ﬂavouring substance (see Section 3.9).
For acute exposure, a margin of safety of 380 for children could be derived based on the higher
APET of 0.3 mg/kg bw per day for a 3-year-old child, which is considered sufﬁcient.
Based on the higher APET (36.4 lg/kg bw per day) and the NOAEL of 100 mg/kg bw per day, a
lowest margin of safety of 2,700 could be derived for long-term exposure in children (Table 5).
Based on the Procedure, the Panel concluded that there is no safety concern for the use of [FL-no:
16.130] as a ﬂavouring substance with modifying properties at the estimated level of dietary exposure
calculated using the APET approach and based on the use levels in food as speciﬁed in Appendix B.
4. Conclusion
The CEF Panel was requested to evaluate 4-amino-5-(3-(isopropylamino)-2,2-dimethyl-3-
oxopropoxy)-2-methylquinoline-3-carboxylic acid [FL-no: 16.130], in the FGE.407 using the Procedure
as referred to in Regulation (EC) No 1334/2008 of the European Parliament and of the Council.
Despite sharing some structural elements with other ﬂavouring substances (e.g. methylquinolines or
anthranilates), these are not sufﬁciently structurally related to the candidate substance. Consequently,
the Panel decided to assess this substance on its own.
4-Amino-5-(3-(isopropylamino)-2,2-dimethyl-3-oxopropoxy)-2-methylquinoline-3-carboxylic acid [FL-no:
16.130] is chemically synthesised and has not been reported to occur in natural source materials of
botanical or animal origin.
Speciﬁcations
The Panel noted that both the parent compound [FL-no: 16.130] and its hemisulfate monohydrate
salt are intended to be added to foodstuffs.
Speciﬁcations including complete purity criteria and identity for the materials of commerce for both
[FL-no: 16.130] and its salt, have been provided and considered adequate. The candidate substance
does not possess chiral centres or double bonds that would give rise to optical or geometrical isomers.
The information provided on the manufacturing process, the composition and the stability of the
ﬂavouring substance and its hemisulfate monohydrate salt were considered sufﬁcient.
Table 5: Summary table of calculated margins of safety
Study type
NOAEL
mg/kg bw/day
Add APET
lg/kg bw/day
Margin of
safety
Adult 90-Day oral toxicity study in the rat 100 14.7 6,800
Child 36.4 2,700
Adult Developmental toxicity study in the rat 1,000 14.7 68,000
Child 36.4 27,000
NOAEL: no-observed-adverse-effect-level; APET: added portions exposure technique; bw: body weight.
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Use and exposure
4-Amino-5-(3-(isopropylamino)-2,2-dimethyl-3-oxopropoxy)-2-methylquinoline-3-carboxylic acid and
its sulfate salt, [FL-no: 16.130], are intended to be used as ﬂavouring substances with modifying
properties6 in speciﬁc food categories.
The chronic dietary exposure to the candidate substance has been estimated using the APET. It is
calculated to be 882 lg/person per day (14.7 lg/kg bw per day for a 60-kg adult) and 547 lg/person
per day (36.4 lg/kg bw per day for a 15-kg 3-year-old child).
The highest acute intake of the candidate substance results from the consumption of non-alcoholic
beverages containing 7 mg/kg of the candidate substance consumed by a 60-kg adult and a 15-kg
3-year-old child. This results in an intake of 6.3 mg/person per day (or 105 lg/kg bw per day for a
60-kg adult) and in an intake of 4.0 mg/person per day (or 265 lg/kg bw per day for a 15-kg 3-year-old
child).
Absorption, distribution, metabolism and elimination
Absorption, distribution, metabolism and elimination (ADME) studies in rats available for [FL-no:
16.130] and its sulfate salt indicate that both forms are poorly absorbed after oral administration and
no signiﬁcant metabolism is expected in the gastrointestinal tract.
Genotoxicity
[FL-no: 16.130] contains a structural alert for genotoxicity in the form of an amino-substituted
aromatic ring. However, the substance gave negative results when tested in a bacterial gene mutation
assay and micronucleus assay in vitro. Based on these results, the Panel concluded that there is no
concern with respect to genotoxicity for the candidate substance [FL-no: 16.130]. Therefore, the
safety of the substance was evaluated according to the Procedure for the evaluation of chemically
deﬁned ﬂavouring substances.
Systemic toxicity
A 90-day systemic toxicity study in the rat has been performed. Dietary administration of [FL-no:
16.130] to CD rats for 13 weeks at doses up to 100 mg/kg bw per day was well tolerated. Based on
the ﬁndings in this study, the NOAEL was considered to be 100 mg/kg bw per day, the highest dose
tested, in both sexes.
Developmental toxicity
In a developmental toxicity study, rats were administered oral doses of 250–1,000 mg/kg bw per
day of the candidate substance. There were no statistically signiﬁcant differences between the treated
and control groups. Therefore, there is no concern for developmental toxicity of [FL-no: 16.130] in rats
at the dose levels up to 1,000 mg/kg bw per day, the highest dose tested.
Safety assessment for acute exposure
Estimates of maximum acute dietary exposure indicate that this would be about 265 lg/kg bw for a
3-year-old child, which is higher than the acute exposure estimate for an adult (105 lg/kg bw per
day). From these data, a margin of exposure of 380 for children can be calculated, which indicates no
concern for acute effects, taking into account that the NOAEL was derived from a 90-day toxicity
study. In addition, no toxicity was observed at dose levels up to 1,000 mg/kg bw per day in a
developmental toxicity study with an exposure period of 14 days.
Safety assessment for long-term exposure
Since no clear structural/metabolic similarity of the candidate substance to ﬂavouring substances in
an existing FGE was identiﬁed, the Panel proceeded with the individual evaluation of the candidate
substance [FL-no: 16.130], according to the EFSA Guidance (EFSA, 2010).
Based on its chemical structure, the substance has been assigned to Cramer class III. The results
of studies on metabolism and pharmacokinetics do not allow to conclude that its metabolites are
innocuous. Accordingly, the candidate substance is evaluated via the B-side of the Procedure scheme.
Based on the comparison of APET with the Cramer class III threshold, a 90-day study and a
6 Regulation (EC) No 1334/2008 of the European Parliament and of the Council of 16 December 2008 on ﬂavourings and certain
food ingredients with ﬂavouring properties for use in and on foods and amending Council Regulation (EC) No 1601/91, Regulations
(EC) No 2232/96 and (EC) No 110/2008 and Directive 2000/13/EC. Ofﬁcial Journal of the European Union, L 354, 34–50.
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developmental toxicity study were required and carried out for this substance. Adequate margins of
safety of 6,800 for adults and 2,700 for 3-year-old children have been calculated on the basis of the
exposure estimates calculated and the NOAEL from the 90-day toxicity study.
Overall, the Panel concluded that using the NOAEL obtained from a 90-day dietary study in rats,
there is no safety concern for [FL-no: 16.130], when used as a ﬂavouring substance with modifying
properties at the estimated level of dietary exposure calculated using the APET approach and based on
the use levels as speciﬁed in Appendix B.
Documentation provided to EFSA
1) BioReliance, 2011. Salmonella Plate Incorporation Mutagenicity Assay: S9632 (SEM 110).
2) BioReliance, 2016. In vitro Mammalian Cell Micronucleus Assay in Human Peripheral Blood
Lymphocytes (HPBL). BioReliance Study No. AE55CP.348.BTL.
3) MPI, 2011a.S9632:A4-weekDietaryAdministrationToxicityStudy inRats (MPIStudyNo.1646-010).
4) MPI,2011b.S9632:A13-weekDietaryAdministrationToxicityStudy inRats (MPIStudyNo.1646-011).
5) Nucro-Technics, 2011a. Bacterial Reverse Mutation Assay of S3333 (Sodium Salt of S9632)
(Nucro-Technics Project No. 245063).
6) Nucro-Technics, 2011b. In Vitro Mammalian Chromosome Aberration Test of S3333 (Sodium
Salt of S9632) in Human Lymphocytes. (Nucro-Technics Project No. 245062).
7) Nucro-Technics, 2011c. In Vivo Mouse Micronucleus Test of S9632. (Nucro-Technics Project
No. 245046).
8) PharmOptima, 2011. Qualitative Metabolic Proﬁling of S9632 Using Human and Rat Mixed
Gender Pooled Hepatic Microsomes (PharmOptima Study No. 2011-110).
9) Senomyx, 2011a. Single IV and Repeated Dose 7-Day Oral PK Study with S9632 in
Sprague-Dawley Rats.
10) Senomyx, 2011b. Relative Bioavailability of S9632 and Its Sodium, Phosphate, and Sulfate
Salts in Sprague-Dawley Rats.
11) Senomyx, 2013. Excretion of S9632 in Urine and Feces Following a Single Oral Dose to Male
and Female Sprague-Dawley Rats.
12) Senomyx, 2016. Responses to Request for Additional Information Application for authorisation
of a ﬂavouring substance, 4-amino-5-(3-(isopropylamino)-2,2-dimethyl-3-oxopropoxy)-2-
methylquinoline-3-carboxylic acid – [FL-no: 16.130], submitted under Commission Imple-
menting Regulations (EC) Nos 872/2012, 234/2011 and 1334/2008 of the European
Parliament and Council. EFSA-Q-2015-00244. Including Appendix A–L.
13) WIL Research, 2012a. An Oral (Gavage) Dose Range-Finding Developmental Toxicity Study
of S9632 in Rats (WIL Research Study no. WIL-884003).
14) WIL Research, 2012b. An Oral (Gavage) Developmental Toxicity Study of S9632 in Rats
(WIL Research Study no. WIL-884004).
15) WILResearch, 2012c.Salmonella/MammalianMicrosomeAssay-SummaryResults forMBR12-210D.
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CEF EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids
CoE Council of Europe
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FEMA Flavor and Extract Manufacturers Association
FGE Flavouring Group Evaluation
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GSFA General Standard for Food Additives
IR infrared
JECFA The Joint FAO/WHO Expert Committee on Food Additives
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Appendix A – Production process and decomposition products
Process description:
3-Hydroxy-2,2-dimethylpropanoic acid ((1) in Figure A.1) is reacted with isopropylamine (2) in
solution in 2-methyltetrahydrofuran at 175°C affording 3-hydroxy-N-isopropyl-2,2-dimethylpropanamide
(3). The so obtained 3-hydroxy-N-isopropyl-2,2-dimethylpropanamide was deprotonated by potassium
tert-butoxide in Me-THF and the resulting alkoxide was reacted with 2-amino-6-ﬂuorobenzonitrile (4).
The resulting 3-(3-amino-2-cyanophenoxy)-N-isopropyl-2,2-dimethylpropanamide was puriﬁed by
crystallisation (5).
Then, 3-(3-amino-2-cyanophenoxy)-N-isopropyl-2,2-dimethylpropanamide is reacted with methyl
acetoacetate at moderate temperature, then cyclised with an excess of sodium ethylate in ethanol to
the intermediate which was directly saponiﬁed into sodium 4-amino-5-(3-(isopropylamino)-2,2-dimethyl-
3-oxopropoxy)-2-methylquinoline-3-carboxylate using sodium hydroxide in water (6).
The insoluble 4-amino-5-(3-(isopropylamino)-2,2-dimethyl-3-oxopropoxy)-2-methylquinoline-3-carboxylic
acid is isolated by precipitation by treatment of sodium 4-amino-5-(3-(isopropylamino)-2,2-dimethyl-3-
oxopropoxy)-2-methylquinoline-3-carboxylatewith sulfuric acid inwater (7= [FL-no: 16.130]).
Using sulfuric acid, the 4-amino-5-(3-(isopropylamino)-2,2-dimethyl-3-oxopropoxy)-2- methylquinoline-3-
carboxylic acid is transformed into its sulfate salt, 3-carboxy-5-(3-(isopropylamino)-2,2-dimethyl-3-oxopropoxy)-
2-methylquinolin-4-aminium sulfate, which is puriﬁed by crystallisation from a solvent mixture (8). The
decarboxylated S9379wasnot detected (Senomyx, 2016).
Information on decomposition products when processed in various product prototypes
[FL-no: 16.130] was found to be stable in model cake, cookie and candy product prototypes under
typical processing conditions as indicated by the high recovery of [FL-no: 16.130] and the absence or
minimal presence of the likely decomposition products.
Figure A.1: Process details for the synthesis of [FL-no: 16.130] and its sulfate
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Dry powder stability of [FL-no: 16.130] and its sulfate salt
As a dry powder, [FL-no: 16.130] and its sulfate salt were found to be stable at 100°C for at least
24 h (Senomyx, 2016). During heating of the dry powder at 175°C, a decarboxylated form of [FL-no:
16.130], referred to as S9379; see structure below) was formed as the single detectable degradant
(Senomyx, 2016).
[FL-no: 16.130] (X=CO2H)
S9379 (X=H)
The above decarboxylation product was also observed as a minor impurity of [FL-no: 16.130]
during the synthesis of various batches of [FL-no: 16.130] (Senomyx, 2016) including the good
manufacturing practice (GMP) batch used for the 90-day and developmental toxicity studies (overall
purity 99%, S9379 0.4%). The identity of this impurity was conﬁrmed by direct comparison with an
authentic sample by liquid chromatography/mass spectrometry (LC/MS) (Senomyx, 2016). The sulfate
salt of [FL-no: 16.130] also produces minor amounts of S9379 under similar conditions (overall purity
99.9%, S9379 < limit of detection of 0.02%).
Evaluation of [FL-no: 16.130] stability in product prototypes
The food product categories that were identiﬁed to be processed at temperatures higher than
100°C were confectionery, breakfast cereals and snacks. Breakfast cereals and snacks are processed at
a wide range of times and temperatures. Model products were selected that could serve as surrogates
that are representative of the most extreme temperature and time conditions (Pariza et al., 1998).
Three key products were evaluated for the potential loss of [FL-no: 16.130] during processing:
cookies, yellow cake and a hard candy. In addition, we have included a ready-to-drink (RTD) coffee
beverage as a typical heat-processed (retort) beverage.
The stability of [FL-no: 16.130] was evaluated in these surrogate product prototypes in order to
determine the recovery of the starting compound and whether the degradation product S9379 formed
in the dry powder under extreme conditions is formed during processing of representative products.
The batch of [FL-no: 16.130] used for the cookies, cake and candy studies already contained ~ 0.4%
of S9379 as an impurity formed during the synthesis of this material. Therefore, the amounts of S9379
found in the cookie, cake and candy studies include a portion present in the starting material. This was
the same batch used for the safety studies. The identiﬁed degradation product measured in product
prototypes was either below the level of quantiﬁcation or minimally formed in all cases.
a. Evaluation of the stability of [FL-no: 16.130] in a cookie prototype
The stability of [FL-no: 16.130] (overall purity 99%, S9379 0.4%) was evaluated in a cookie
prototype baked at 204°C for 8 min. The per cent [FL-no: 16.130] remaining, as well as the presence
of the breakdown product (S9379), was evaluated by liquid chromatography with tandem mass
spectrometry (LC–MS/MS) (Senomyx, 2016). No statistically signiﬁcant loss of [FL-no: 16.130] was
observed (nominal concentration, 5.0 mg/kg; measured concentration, 5.1–5.8 mg/kg). The measured
concentration of S9379 was 0.043 mg/kg, equivalent to 0.9% of the [FL-no: 16.130] nominal level.
Overall, the vast majority of [FL-no: 16.130] remained intact through the process of preparation and
baking, as indicated by the high percentage of [FL-no: 16.130] recovered, as well as the low level of
potential degradant measured.
In another test, [FL-no: 16.130] sulfate salt (overall purity 99.9%, S9379 < limit of detection of
0.02%) was added to another similar sugar cookie ingredient mix and baked at 177°C for 10 min (i.e.
lower temperature than above but 2 min longer). The recovery of [FL-no: 16.130] sulfate salt (18 mg/kg)
was found to be 100% (RSD = 6.7%, N = 3). The concentration of the potential degradant S9379 was
0.02 mg/kg, corresponding to 0.1% of the nominal [FL-no: 16.130] sulfate salt concentration.
b. Evaluation of the stability of [FL-no: 16.130] in a cake prototype
The stability of [FL-no: 16.130] (overall purity 99%, S9379 0.4%) was evaluated in a yellow cake
prototype baked at 177°C for 30 min. The per cent [FL-no: 16.130] remaining, as well as the presence
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of the degradant (S9379) was evaluated by LC–MS/MS (Senomyx, 2016). No statistically signiﬁcant
loss of [FL-no: 16.130] was observed (nominal concentration, 5.0 mg/kg; measured concentration,
5.1–6.1 mg/kg). The measured concentration of S9379 was 0.041 mg/kg, equivalent to 0.82% of the
[FL-no: 16.130] nominal level. Overall, the vast majority of [FL-no: 16.130] remained intact through
the process of preparation and baking, as indicated by the high percentage of [FL-no: 16.130]
recovered, as well as the low level of the potential degradant measured.
c. Evaluation of the stability of [FL-no: 16.130] in a hard candy prototype
The stability of [FL-no: 16.130] (overall purity 99%, S9379 0.4%) was evaluated in a hard candy
prototype, which involved heating to a boil until the mixture reached 149°C (~30 min) followed by
cooling. The per cent [FL-no: 16.130] remaining, as well as the presence of the potential degradant
(S9379), was evaluated by LC–MS/MS (Senomyx, 2016). The measured [FL-no: 16.130] represents
87% of the nominal concentration at 15 mg/kg (RSD = 2.8%, n = 3). The measured concentration of
S9379 was 0.14 mg/kg, equivalent to 0.94% of the [FL-no: 16.130] nominal level. Overall, the
majority of [FL-no: 16.130] remained intact through the process of preparation and cooking, as
indicated by the percentage of [FL-no: 16.130] recovered, as well as the low level of potential
degradant measured.
In another test, [FL-no: 16.130] sulfate salt (overall purity 99.9%, S9379 < limit of detection of
0.02%) was used while the candy ingredients and cooking conditions kept the same. The recovery of
[FL-no: 16.130] sulfate salt (nominal concentration at 24 mg/kg) was found to be 104% (RSD = 5%,
N = 6). The concentration of the potential degradant S9379 was 0.04 mg/kg, corresponding to 0.4%
of the nominal sulfate salt concentration.
In summary, [FL-no: 16.130] was found to be stable in model cake, cookie and candy product
prototypes under typical processing conditions. The amount of potential breakdown product (S9379)
measured represented < 1% of the corresponding nominal [FL-no: 16.130] concentration (Table A.1
below). Considering that S9379 was already present as an impurity at the level of ~ 0.4% in the batch
of [FL-no: 16.130] used in these stability studies, the true level of S9379 generated in the preparation
and processing for the prototypes is less than the level indicated by the measured S9379
concentration.
Table A.1: Summary of the analysis of [FL-no: 16.130] and the potential degradant (S9379) in
product prototypes. The percentage in a parenthesis for the degradant is the % of the nominal
concentration represented by the measured degradant
Product
prototype
[FL-no: 16.130]
Nominal
concentration,
mg/kg
[FL-no: 16.130]
Measured
concentration,
mg/kg
[FL-no: 16.130]
Mean measured
concentration,
mg/kg
Decarboxylation
product, mg/kg
(% of [FL-no:
16.130])
Cake 5 5.1–6.1 5.8 0.041 (0.82)
Cookie 5 5.1–5.8 5.4 0.043 (0.86)
Candy 15 12.7–13.4 13.1 0.14 (0.94)
FL-no: FLAVIS number.
d. Evaluation of [FL-no: 16.130] stability after retort in a ready to drink coffee beverage
In order to further evaluate the stability of [FL-no: 16.130] in aqueous products, the stability of
[FL-no: 16.130] sulfate salt (overall purity 99.9%, S9379 < limit of detection of 0.02%) was evaluated
under retort processing conditions in a RTD coffee beverage, which also included a follow-on shelf-life
study phase (Senomyx, 2016).
Three retort coffee beverage formulas were prepared: 1) RTD coffee beverage prototype containing
4% sucrose (no modiﬁer), 2) RTD coffee beverage containing 4% sucrose and 10 mg/kg [FL-no:
16.130] sulfate salt and 3) RTD coffee beverage containing 10 mg/kg [FL-no: 16.130] sulfate salt (no
sucrose). Each formula was packaged in 200 9 390 g foil retort pouches (16 ounce) and processed in
a still, steam air overpressure retort to commercial sterility.
Samples were stored at 4°C or under accelerated conditions of 30°C, with analysis at 0, 1, 2, 3, 4,
5 and 6 months. It was assumed that 1 month in accelerated storage is equal to 2 months in ambient
storage. Samples were evaluated for pH, visually, by sensory and the concentration of compound was
conﬁrmed by LC/MS.
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No changes were observed in pH, visual inspection or sensory under any condition. The analytical
results demonstrated no signiﬁcant degradation of [FL-no: 16.130] during the processing conditions or
during storage at 4°C (control) or 30°C (accelerated) for up to 6 months (Senomyx, 2016).
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Calculation of the Dietary Exposure – APET
Chronic Dietary Exposure
Adults (‘Added Portions Exposure Technique’ [APET]7).
On the Basis of Normal Occurrence Level from Added Flavourings
The APET is calculated by adding the highest contribution from one portion of food and one portion
of beverages:
Solid Food: The maximum intake of 447 lg/person per day will be from food categories 5.2
(Confectionery, including hard and soft candy, nougats, etc., other than 05.1, 05.3 and 05.4; 30 g/day)
or 6.3 (Breakfast cereals, including rolled oats; 30 g/d) with the normal combined occurrence level of
14.9 mg/kg food.
Beverage: The maximum intake of 435 lg/person per day will be from category 14.2.6 (Distilled
spirituous beverages containing more than 15% alcohol; 30 g/d) with the normal combined occurrence
level of 14.5 mg/kg food.
The total APET will be 882 lg/person per day corresponding to 14.7 lg/kg bw per day for a 60-kg
person.
Children (3-year-old child of 15-kg body weight)
Food subcategories resulting in the highest potential dietary exposure:
Solid Food: The maximum intake will be 282 lg/child per day from food categories 5.2
(Confectionery, including hard and soft candy, nougats, etc., other than 05.1, 05.3 and 05.4; 30 g/day)
or 6.3 (Breakfast cereals, including rolled oats; 30 g/d) with the normal combined occurrence level
(14.9 mg/kg food), taking into account a portion size reduction factor of 0.63 for children (EFSA,
2010).
Beverage: The maximum intake of 265 lg/child per day will be from category 14.1c (Other non-
alcoholic (‘soft’) beverages (expressed as liquid); 300 g/d) with the normal combined occurrence level
of 1.4 mg/kg food, taking into account a portion size reduction factor of 0.63 for children (EFSA,
2010).
The total APET will be 547 lg/child per day corresponding to 36.4 lg/kg bw per day for a 15 kg
child.
Conclusion
The total APET values are 14.7 lg/kg bw per day for 60-kg adults and 36.4 lg/kg bw per day for
15-kg children. In terms of per capita intake, the adult value of 882 lg/day is the higher.
Acute Dietary Exposure
The calculation was based on the maximum use levels and large portion size, i.e. three times
standard portion size (see Table B.1).
Although the substance is not intended to be used in food categories speciﬁcally intended for
infants and toddlers, these could still be exposed through consumption of foods from the general food
categories, which may contain the substance. However, at present there is no generally accepted
methodology to estimate exposure in these age groups resulting from consumption of foods from the
general categories.
Adults
On the basis of maximum occurrence level of 7 mg/kg for food categories 14.1c (Other non-
alcoholic (‘soft’) beverages (expressed as liquid) or 14.2.1 (Beer and malt beverages) and a large
portion size of 900 g/d (3 9 300 (standard portion size for both food categories mentioned)), the
highest acute exposure level for adults is 6,300 lg/person per day, which is equivalent to 105 lg/kg
bw per day.
Children (3-year-old child of 15-kg body weight)
On the basis of maximum occurrence level of 7 mg/kg for food categories 14.1c (Other non-
alcoholic (‘soft’) beverages) (expressed as liquid) and a large portion size of 900 g/d (3 9 300
7 The APET has been calculated based on the occurrence levels in the food subcategories reported in the above table, with the
exclusion of categories 13.2 (complementary foods for infants and young children).
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(standard portion size for the food categories mentioned)), and taking into account a portion size
reduction factor of 0.63 for children (EFSA, 2010), the highest acute exposure level for a child is
3,970 lg/person per day, which is equivalent to 265 lg/kg bw per day.
Conclusion
The highest8 acute exposure value for [FL-no: 16.130] value is 265 lg/kg bw per day, derived from
the scenario of a 3-year-old child with a 15-kg body weight.
Cumulative Dietary Exposure to [FL-no: 16.130]
There is no other ﬂavouring substance structurally and metabolically related to [FL-no: 16.130].
Moreover, the candidate substance is chemically synthesised and is not expected to occur naturally in
food. Consequently, the cumulative dietary exposure estimate is not applicable in this case.
8 The highest value obtained among adults and children of all ages.
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Appendix C – Genotoxicity
Theoretical considerations
With reference to the structure alerts for genotoxicity (Ashby and Tennant, 1991; Benigni et al.,
2008), [FL-no: 16.130] contains a structural alert for genotoxicity in the form of an amino-substituted
aromatic ring. In as much as quinoline and some alkyl quinolines are known to be metabolised to give
N-oxides (EFSA, 2008), this structural element constitutes a structural alert for genotoxicity (Benigni
et al., 2008).
In vitro studies
Bacterial reverse mutation assay
A preliminary study was carried out in Salmonella Typhimurium strains, TA98 and TA100 in the
presence and absence of metabolic activation (S9-mix). The candidate substance [FL-no: 16.130]
(purity > 98%) was tested in S. Typhimurium strains TA98 and TA100 with a plate incorporation
method at the following concentrations: 0, 1.5, 5.0, 15, 50, 150, 500, 1,500 and 5,000 lg/plate using
dimethyl sulfoxide (DMSO) as a solvent. 2-Nitroﬂuorene 1 lg/plate was included as a positive control.
Duplicate plates were used for each concentration. No precipitates were observed at any
concentrations. Therefore, the test article was evaluated at the maximum recommended concentration
for a soluble non-toxic compound. The treatment with [FL-no: 16.130] did not result in bacterial
toxicity or mutagenic activity. Signiﬁcant increases in the number of revertant colony counts were
observed in the concurrent positive control compared to the corresponding negative control,
conﬁrming the sensitivity of the test system and the activity of the S9 mix. The candidate substance
[FL-no: 16.130] was not mutagenic in TA98 and TA100 under the test conditions of this study
(BioReliance, 2011).
The sodium salt of the candidate substance (purity > 99%) was evaluated for its potential to
induce point mutations in S. Typhimurium strains, TA98, TA100, TA1535, TA1537 and Escherichia coli
strain WP2 uvrA (Nucro-Technics, 2011a). The study was performed according to the OECD Test
Guideline 471 (OECD, 1997a). The concentrations of [FL-no: 16.130] sodium salt investigated for both
the plate incorporation and pre-incubation tests, were 0, 51, 130, 320, 800, 2,000 and 5,000 lg/plate.
The lowest concentration of 51 lg/plate was not investigated in experiments with metabolic activation
and for strain TA1535 without metabolic activation (OECD, 1997a). At the end of the incubation
period, precipitate was not visible at any concentration. Therefore, the test article was completely
soluble in the test system. No toxicity was observed at any concentration including the highest of
5,000 lg [FL-no: 16.130] sodium salt per plate. Therefore, the test article was evaluated at the
maximum recommended concentration for a soluble non-toxic compound (OECD, 1997a).
In both the plate incorporation and pre-incubation test, with or without metabolic activation,
[FL-no: 16.130] sodium salt did not induce any increase in revertants over the concurrent negative
controls.
The negative controls (DMSO) for each tester strain were within the historical negative control data.
All concurrent positive controls (for experiments without S9-mix: sodium azide, 2-nitroﬂuorene,
methyl methanesulfonate and 9-aminoacridine; for experiments with S9-mix: benzo[a]pyrene and 2-
aminoanthracene, cyclophosphamide monohydrate) induced at least a 3.1-fold increase in colony
counts per plate when compared to the corresponding negative controls and were at levels similar to
the historical positive control data.
The sodium salt of [FL-no: 16.130] was not mutagenic to S. Typhimurium strains TA98, TA100,
TA1535, TA1537 and E. coli strain, WP2 uvrA, under the test conditions of this study.
Bacterial reverse mutation assay with S9379
An Ames assay was performed on S9379, a decomposition product formed by decarboxylation of
[FL-no: 16.130] (4-amino-5-(3-(isopropylamino)-2,2-dimethyl-3-oxopropoxy)-2-methylquinoline). S9379
was tested in S. Typhimurium strains, TA98 and TA100 in the presence or absence of metabolic
activation (S9-mix) at 1, 5, 10, 50, 100, 500, 1,000 and 5,000 lg/plate. The plate incorporation
method was applied. The positive controls without metabolic activation were 2-nitroﬂuorene and
sodium azide. The positive control with metabolic activation for both strains was 2-aminoanthracene.
DMSO was used as the vehicle control. Precipitates were not observed in either strain with or without
metabolic activation at concentrations up to 5,000 lg/plate. Cytotoxicity (reduction in the background
lawn) was observed at 5,000 lg/plate in both strains without metabolic activation; the highest
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concentration evaluated for mutagenicity in the absence of metabolic activation was 1,000 lg/plate.
There was no increase in the number of revertant colonies as compared with the vehicle control in
either strain with or without S9-mix. It was concluded that S9379 was not mutagenic under the test
conditions of this study (WIL Research, 2012c).
In vitro micronucleus assay
The purpose of the study by BioReliance (2016) was to evaluate the potential of the sulfate salt
(S1638) of the candidate substance [FL-no: 16.130], or its potential metabolites, to induce micronuclei
in human peripheral blood lymphocytes (HPBL). The study was performed according to the OECD Test
Guideline 487 (OECD, 2014).
[FL-no: 16.130] sulfate salt was tested in cultured human peripheral lymphocytes from a single
young healthy female donor using cytokinesis-block methodology both in the presence and absence of
an exogenous metabolic activation system (S9-mix, rat liver S9 from rats induced with AroclorTM 1254).
Cells were treated for 4 h (and 20 h recovery period) with and without S9-mix or for 24 h without
S9-mix. S1638 was dissolved in N-methyl-2-pyrrolidone that was used as a vehicle control, a further
negative control of untreated cells was included. A preliminary toxicity assay was carried out at nine
concentrations ranged from 0.2 to 2,000 lg/mL. The levels of cytotoxicity, measured as cytokinesis-
blocked proliferation index (CBPI) relative to the vehicle control, at the highest concentration tested
were 31% and 20% in 4-h exposure groups with and without S9, respectively, and 45% in 24-h
exposure group with S9-mix. Based on these results, the concentrations chosen for the micronucleus
assay ranged from 100 to 2,000 lg/mL for all three treatment conditions.
In the micronucleus assay, cytotoxicity (55  5% CBPI relative to the vehicle control) was not
observed at any concentration tested at 4 + 20 h with or without S9-mix. Cytotoxicity was observed at
the highest concentration tested (2,000 lg/mL) in cells treated for 24 h. The concentrations selected
for evaluation of micronuclei were 500, 1,000 and 2,000 lg/mL for all three treatment conditions. No
signiﬁcant or concentration-dependent increases in micronuclei induction were observed in any
treatment with or without S9-mix (p > 0.05; Fisher’s Exact and Cochran-Armitage tests) (BioReliance,
2016).
The Panel concluded that [FL-no: 16.130] sulfate salt was negative for the induction of micronuclei
in HPBL in the presence and absence of metabolic activation.
Chromosomal aberration test
The sodium salt of the candidate substance [FL-no: 16.130] (purity > 99%) was investigated in a
chromosomal aberration test for its potential to induce structural chromosomal aberrations in primary
human lymphocytes (Nucro-Technics, 2011b). The study was performed according to the OECD Test
Guideline 473 (OECD, 1997b).
Duplicate cultures of human lymphocytes were treated with [FL-no: 16.130] sodium salt under
three different conditions: 3-h exposure in the absence or presence of metabolic activation (S9-mix);
20-h exposure in the absence of S9-mix.
The concentrations of [FL-no: 16.130] sodium salt tested for the 3-h treatment without S9-mix
were 0, 3.91, 7.81, 15.6, 31.3, 62.5, 125, 250 and 500 lg/mL.
The concentrations of [FL-no: 16.130] sodium salt tested for the 3-h treatment with S9-mix and
20-h treatment without S9-mix were 0, 62.5, 125, 250 and 500 lg/mL.
The vehicle control was DMSO. Positive controls were mitomycin C, used at 0.5 and 1.0 lg/mL as a
positive control for 3-h treatment and 0.1 and 0.2 lg/mL for 20-h treatment in the absence of S9-mix.
Cyclophosphamide, was used at 10, 20 and 40 lg/mL as a positive control for treatment with S9-mix.
Only the highest exposure concentration of 500 lg [FL-no: 16.130] sodium salt per mL produced
precipitates in the treatment medium at the beginning of the treatment period. Therefore, the test
article was tested at the limit of solubility (OECD, 1997b). The pH and osmolality of all treated cultures
were well within the normal physiological ranges.
For all conditions, cells were harvested 20 h after the initiation of the treatment, approximately 2 h
before harvesting, Colcemid® was added to cultures at 0.1 lg/mL to arrest cells in metaphase.
Based on the relative cell growth (RCG) and the relative mitotic index (RMI), only the highest three
concentrations were selected for chromosomal aberration analysis for each treatment condition. At
least 100 metaphase cells from each culture were examined.
The treatment of 3 h without S9-mix, at 0, 125, 250 and 500 lg/mL, resulted in 3.0, 3.5, 2.0 and
2.5% of cells with chromosomal aberrations, respectively. Endoreduplicated cells were not observed at
any of the analysed concentrations. A low incidence of polyploid cells (0.5%) was detected at 250 lg/mL.
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The treatment of 3 h with S9-mix at 0, 125, 250 and 500 lg/mL resulted in 3.5, 5.0, 4.0 and 2.5%
of cells with chromosomal aberrations, respectively. Endoreduplicated cells were not observed at any
of the analysed concentrations. A low incidence of polyploid cells (0.5%) was detected for 50 lg/mL.
The treatment of 20 h without S9-mix at 0, 125, 250 and 500 lg/mL, resulted in 1.5, 2.0, 1.0 and
3.0% of cells with structural chromosomal aberrations, respectively. Polyploid and endoreduplicated
cells were not observed for any of the analysed concentrations.
All concurrent positive controls induced signiﬁcant numbers (P < 0.001) of cells with chromosomal
aberrations.
The percentage of cells with structural or numerical chromosomal aberrations in the [FL-no:
16.130] sodium salt-treated HPBL cultures was not statistically signiﬁcantly increased relative to
solvent control at any concentration tested in the presence or absence of S9-mix. The positive and
solvent controls fulﬁlled the requirements for a valid test.
The Panel concluded that the chromosomal aberration test was negative. The in vitro genotoxicity
studies are summarised in Table C.1.
In vivo studies
Micronucleus assay
The candidate substance, [FL-no: 16.130] (purity > 99%), was tested in a mouse bone marrow
micronucleus assay (Nucro-Technics, 2011c). The assay was performed in accordance with the OECD
Test Guideline 474 (OECD, 1997c).
In the range-ﬁnding study, three groups of Swiss Albino (CD-1) mice, each containing two males
and two females, were administered with [FL-no: 16.130], through oral gavage, at 500, 1,000 or
2,000 mg/kg bw. The test article was suspended in 1% aqueous methyl cellulose. Based on the results
of this preliminary study, the dose levels of 500, 1,000 and 2,000 mg/kg bw per day were chosen for
the main study. Since there was no substantial difference in toxicity between genders, only male mice
were used for the main study. The range-ﬁnding study was not conducted under GLP conditions.
In the main study, ﬁve groups of Swiss Albino (CD-1) mice were dosed via gavage with: 0, 500,
1,000 or 2,000 mg [FL-no: 16.130]/kg bw or with 70 mg cyclophosphamide/kg bw (positive control).
Animals from each group were sacriﬁced at 24, 36 or 48 h after dosing (seven animals per time
point). For each sacriﬁced animal, bone marrow was recovered and pooled from both femora. Bone
marrow smears were prepared, ﬁxed and stained (May-Grunwald/Giemsa) for evaluation. Two
thousand polychromatic erythrocytes (PCE) per animal were scored for the presence of micronuclei. In
addition, the number of normochromatic erythrocytes (NCE) with micronuclei was scored. The PCE/NCE
ratio within 200 cells was determined for each animal. The number of PCEs with micronuclei was
analysed for statistically signiﬁcant differences (at p ≤ 0.05) using Kruskal–Wallis one-way analysis of
variance on ranks. The analysis was carried out for each dose level at each of the 3 time points. No
statistically signiﬁcant decrease in the PCE/NCE ratio was observed at any concentration tested. There
were no statistically signiﬁcant differences in the number of PCE with micronuclei between the test
article (all three dose levels) and the negative control group. Statistically signiﬁcant differences
(p ≤ 0.05) at 24, 36 and 48 h in the number of PCEs with micronuclei in the positive control group
when compared to both the negative control group were observed.
Based on the above results, the test article, [FL-no: 16.130], did not induce micronuclei in the
mouse micronucleus test at the dose levels up to 2,000 mg/kg bw, administered by a single oral
gavage to mice. Due to the lack of cytotoxicity in the bone marrow cells or any other demonstration of
bone marrow exposure, the results of this study have to be considered of limited relevance
(Table C.2).
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Appendix D – Absorption, distribution, metabolism and elimination
A short-term study was performed to determine the toxicokinetic parameters and oral bioavailability
of the candidate substance by either a single intravenous administration or up to 7 days of oral dosing
(gavage) in male and female Sprague–Dawley rats (Senomyx, 2011a).
The candidate substance was poorly bioavailable by the oral route (%F = 0.53–1.19%) and rapidly
eliminated after either intravenous (T1/2 < 0.3 h) or oral administration (T1/2 < 1.2 h). At 100 mg/kg
per day, the combined mean Cmax on day 7 was 154 ng/mL (0.428 lM) and the combined mean
AUC0–24 was 232 h*ng/mL. Based on AUClast and Cmax, the exposure to the candidate substance in
plasma was roughly proportional with dose. Exposure (AUClast) to the candidate substance was not
signiﬁcantly different in either male or female rats on day 7 vs day 1 of dosing. No signiﬁcant
accumulation of the candidate substance was found in plasma after repeated dosing for seven
consecutive days.
In order to further evaluate its toxicokinetics after dietary administration, a 90-day feeding study
was carried out in CD®[Crl:CD®(SD)] rats on the candidate substance (MPI, 2011b). There were no
consistent differences in the toxicokinetic parameters calculated for male and female rats on day 7 or
day 90. Systemic exposure, as estimated by AUC0–24 and Cmax, increased in approximate proportion to
the increase in dose between 30 and 100 mg/kg per day. Combined mean Tmax values ranged from
1.5 to 3 h on day 7 and from 1.5 to 7.5 h on day 90. Combined mean Tmax was generally longer at 60
and 100 mg/kg per day than at 30 mg/kg per day on day 90. Consistent with results from the 7-day
pharmacokinetic study in rats at 100 mg/kg per day, the combined mean Cmax on day 7 was 114 ng/mL
(0.317 lM) and the combined mean AUC0–24 was 1,040 h*ng/mL. Systemic exposure to [FL-no:
16.130] was higher on day 90 than on day 7. Combined mean accumulation ratios ranged from 1.1 to
2.8 for AUC0–24 and ranged from 1.8 to 5.2 for Cmax.
A qualitative metabolic proﬁling study of the candidate substance was performed using rat and
human hepatic microsomes (PharmOptima, 2011). Based on concerted and detailed analysis of the full
scan mass spectra of study samples, the candidate substance was not metabolised by the rat or
human microsomes during the 60-min incubation period. Mass chromatograms were generated for the
common Phase I transformations of M+16, M+32, M16, M32, M+18, M18, M42 and M44
(decarboxylation) and M141 (O-dealkylation of the 2,2-dimethyl-N-(propan-2-yl)-propanamide
moiety). Full scan and mass chromatograms were examined in detail and printed to support that no
metabolism was observed above the level of 0.1% of the candidate substance. No Phase I
biotransformations of the candidate substance were observed in either the rat or human microsomal
incubation samples to the level of 0.1%.
In order to exclude the possibility that [FL-no: 16.130] is undergoing presystemic metabolism by
the gut microﬂora, the current study investigated the amount of [FL-no: 16.130] recovered in the
faeces and urine following a single oral dose (PO) in male and female rats (Senomyx, 2013).
Rats were orally dosed with 10 mg/kg of [FL-no: 16.130], and faeces and urine were collected at
four time points, 8, 24, 48, and 72 h after dosing. Diluted faecal extracts and urine samples were
analysed by liquid chromatography with mass spectrometry (LC–MS/MS). An average of 86.2% from
male rats and 91.4% from female rats of [FL-no: 16.130] was recovered from faeces and urine over
the combined 72-h collection period. The vast majority of the compound was excreted during the
8–24-h time interval, the majority of which was recovered from the faeces (75.5–99.5% in faeces vs
0.1–0.6% in urine). These results support that [FL-no: 16.130] is poorly absorbed and mainly excreted
unchanged.
Oral bioavailability of sodium salt of [FL-no: 16.130] in rats
As the bacterial reverse mutations tests for the candidate substance were carried out on the
sodium salt of the candidate substance, the oral bioavailability of this salt was compared to that of the
candidate substance. As part of this study, the bioavailabilities of the phosphate and sulfate salt forms
of the candidate substance were compared as well (Senomyx, 2011b). Four groups of four male
Sprague–Dawley rats were treated by gavage with a single dose of 30 mg/kg of either the free acid of
[FL-no: 16.130] or its sodium salt or its phosphate salt or its sulfate salt in 1% methylcellulose. Blood
samples were taken from a jugular catheter at approximately 15, 30 min, 1, 2, 4, 8 and 24 h after
gavage administration. Plasma samples were analysed using LC–MS/MS with an internal standard. The
plasma AUClast and Cmax of the sodium salt relative to that of the parent candidate substance were
89.4% and 99.4%, respectively (after correcting for differences in molecular weight). Similarly, the
plasma AUClast and Cmax of the phosphate salt relative to that of the candidate substance were 112%
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and 99.9%, respectively. Finally, the plasma AUClast and Cmax of the sulfate salt was relative to that of
the parent candidate substance were 136% and 114%, respectively. Based on AUClast, Cmax and Tmax
data, all three salt forms of the candidate substance are not signiﬁcantly different and considered to
be bioequivalent to the candidate substance in terms of systemic exposure.
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Appendix E – Toxicity
28-day range-ﬁnding toxicity study in rats
The purpose of this (non-good laboratory practice (GLP)) study was to evaluate the potential
toxicity of the candidate substance, [FL-no: 16.130] (purity > 99%), in rats after dietary administration
for 28 days (MPI, 2011a) in order to select doses for a 13-week subchronic toxicity study in rats.
Three treatment groups of ﬁve male and ﬁve female CD®[Crl:CD®(SD)] rats were administered the
test article at the intended dose levels of 10, 30 and 100 mg/kg body weight (bw) per day. The actual
average dose levels were within 5% of the intended dose levels, based on feed consumption and
measured body weights and concentrations in the feed. One additional group of ﬁve animals/sex
served as the control and received the vehicle diet. The vehicle or test article diet was available
ad libitum for 28 consecutive days.
Observations for morbidity, mortality and the availability of food and water were conducted twice daily
for all animals. Observations for clinical signs were conducted weekly. Body weights were measured and
recorded on days 1, 1, 4, 5, 11, 14, 21 and 28. Food consumption was measured and recorded on days
4, 7, 11, 14, 21 and 28, and compound consumption was calculated. Ophthalmoscopic examinations
were conducted pretest and prior to the terminal necropsy. Blood and urine samples for clinical pathology
evaluations were collected from all animals prior to the terminal necropsy. At study termination, necropsy
examinations were performed and only the liver was microscopically examined for animals at 0 and
100 mg/kg per day.
No test article-related effects were noted for any parameter examined. One female at 100 mg/kg
bw per day exhibited mildly increased lymphocytes but being an isolated incidence this was not
considered related to test article administration. One male at 100 mg/kg bw per day exhibited
markedly increased bile acids and mild to moderate increases of aspartate aminotransferase, alanine
aminotransferase, c-glutamyltransferase, and sorbitol dehydrogenase. These are all related to liver
function and injury but because this was an isolated occurrence they were believed to be incidental in
this animal and not test article related. Group mean spleen weights were increased in males of the
100 mg/kg bw per day group which was the result of one animal having a spleen weight
approximately twice that of the other animals of the group; this increased spleen weight was not
considered to be test article related. As a result, the no-observed-effect-level (NOEL) following 28 days
of dietary administration was set at 100 mg/kg bw per day, the highest dose level tested, in male and
female rats. In case any of the above described effects in single animals at the highest dose (100 mg/kg
bw per day) actually represents the ﬁrst sign of a systematic toxicity, this must be expected to be
disclosed in the below described 90-day study where 100 mg/kg bw per day is chosen as the highest
dose administered.
Repeated 90-day oral toxicity study in rats
A 90-day feeding study was carried out in rats on the candidate substance, [FL-no: 16.130]
(purity > 99%), in order to evaluate its subchronic toxicity in rats after dietary administration for
13 weeks (90 days) (MPI, 2011b).
The study is based on the US Food and Drug Administration (FDA) Toxicological Principles for the
Safety of Food Ingredients and conducted in accordance with the FDA GLP.
The candidate substance was administered in the diet to four groups of 20 male and 20 female
CD®[Crl:CD®(SD)] rats at the intended dose levels of 0 (control), 30, 60 and 100 mg/kg bw per day.
The actual average dose levels were within 5% of the intended dose levels based on feed
consumption and measured body weights and concentrations in the feed. The vehicle or diet
containing test article was available ad libitum for 13 weeks.
Additionally, one control group of three animals/sex and three treated groups of six animals/sex per
group served as part of the toxicokinetic study reported in Appendix D.
Observations for morbidity, mortality and the availability of food and water were conducted twice
daily for all animals. Cage-side clinical observations were conducted once daily for main study.
Functional Observation Battery (FOB) and Motor Activity (MA) evaluations were conducted prior to
testing and again at the same time of day during the 13th week of test article administration for all
animals. Body weights were measured and recorded on day 1 and then weekly throughout the study.
Food consumption was measured and recorded weekly. Compound consumption was calculated weekly
on all main study animals. Neurobehavioral examinations were conducted prior to initiation of test
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article administration and then weekly during study. Ophthalmoscopic examinations were conducted
pretest on all animals and prior to scheduled necropsy.
Samples for haematology and clinical chemistry evaluations were collected from 10 animals/sex per
group on days 14 and 45, and again prior to termination. Urinalysis and samples for coagulation
evaluations were collected prior to termination only. At study termination, necropsy examinations were
performed and organ weights were recorded for all animals, excluding animals from the toxicokinetic
groups, and appropriate organ weight ratios were calculated (relative to body and brain weights).
Microscopic examination of ﬁxed haematoxylin and eosin-stained parafﬁn sections were performed on
sections of tissues from the control and high-dose (100 mg/kg bw per day) groups.
There were no test article-related effects noted for any parameter examined. There were no
macroscopic or microscopic ﬁndings or toxicologically signiﬁcant test article-related organ weight
changes noted at any dose level. As a result, the no-observed-adverse-effect-level (NOAEL) following
13 weeks of dietary administration was 100 mg/kg per day, the highest dose level tested, in male and
female rats. Formulation analysis demonstrated that the formulation preparation method produced
homogeneous preparations (RSD < 20%).
The results of the toxicokinetic part of this study are reported in Appendix D.
Dose range-ﬁnding study for a developmental toxicity test in rats
The objective of the study was to determine the dosage levels of the candidate substance, [FL-no:
16.130] (purity > 98.9%), to be used in a deﬁnitive developmental toxicity study conducted in
accordance with the OECD Guidelines for Testing of Chemicals Guideline 414 (Prenatal Developmental
Toxicity Study), (WIL Research, 2012a).
The candidate substance in 1% methyl cellulose [400 cps] was administered orally by gavage to
four groups of eight bred female Crl:CD(SD) rats twice daily (approximately 4 h apart) from gestation
days 6 through 20. The total daily dosage levels were 125, 250, 500 and 1,000 mg/kg bw per day
administered at a dosage volume of 10 mL/kg per dose. A concurrent control group composed of eight
bred females received the vehicle on a comparable regimen. The females were approximately
14 weeks of age at the initiation of dose administration. All animals were observed twice daily for
mortality and morbidity. Clinical observations, body weights and food consumption were recorded at
appropriate intervals. On gestation day 21, a laparohysterectomy was performed on each female. The
uteri, placentas and ovaries were examined and the numbers of fetuses, early and late resorptions,
total implantations and corpora lutea were recorded. Gravid uterine weights were recorded, and net
body weights and net body weight changes were calculated. The fetuses were weighed, sexed and
examined for external malformations and developmental variations.
All females survived to the scheduled necropsy on gestation day 21. There were no remarkable
maternal clinical or macroscopic ﬁndings noted at any dosage level. Mean body weights, body weight
gains, net body weights, net body weight gains, gravid uterine weights and food consumption in the
125, 250, 500 and 1,000 mg/kg bw per day groups were unaffected by test article administration.
Intrauterine growth and survival were unaffected by test article administration at all dosage levels
tested. A single low-weight fetus in the 1,000 mg/kg bw per day group was noted with
craniorachischisis, microphthalmia, gastroschisis, tarsal ﬂexure, bent tail and anal atresia. There were
no other external malformations or external developmental variations noted in this study.
There were no remarkable maternal clinical or macroscopic ﬁndings and mean maternal body
weight, body weight gain and food consumption were unaffected by test article administration at all
dosage levels evaluated. Additionally, intrauterine growth and survival and fetal morphology were
unaffected by test article administration at all dosage levels tested. Based on the results of this study,
the dosage levels of 250, 500 and 1,000 mg/kg bw per day were selected for a deﬁnitive embryo/fetal
development study of the candidate substance administered orally by gavage to inbred Crl:CD(SD)
rats.
Developmental toxicity (prenatal) study in rats
The objective of the study was to determine the potential of the candidate substance, [FL-no:
16.130] (purity > 98.9%), to induce developmental toxicity after maternal exposure from implantation
to 1 day prior to expected parturition, to characterise maternal toxicity at the exposure levels tested
and to determine a NOAEL for maternal and developmental toxicity (WIL Research, 2012b). The study
was conducted in general accordance with the OECD Test Guideline 414 (OECD, 2001) and the US FDA
Redbook 2000 (Toxicological Principles for the Safety Assessment of Food Ingredients, as updated)
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(FDA, 2007) and the Guidelines for Reproduction and Development Studies, January 2001 (WIL
Research, 2012b).
The test article, [FL-no: 16.130], in 1% methylcellulose [400 cps] was administered orally by
gavage to three groups of 25 bred female Crl:CD(SD) rats twice daily (approximately 4 h apart) from
gestation days 6 through 20. The total daily dosage levels were 250, 500 and 1,000 mg/kg bw per day
administered at a dosage volume of 10 mL/kg per dose. A concurrent control group composed of 25
bred females received the vehicle (1% methylcellulose [400 cps]) on a comparable regimen. The
females were approximately 14 weeks of age at the initiation of dose administration. All animals were
observed twice daily for mortality and morbidity. Clinical observations, body weights and food
consumption were recorded at appropriate intervals. On gestation day 21, a laparohysterectomy was
performed on each female. The uteri, placentas and ovaries were examined and the numbers of
fetuses, early and late resorptions, total implantations and corpora lutea were recorded. Gravid uterine
weights were recorded and net body weights and net body weight changes were calculated. The
fetuses were weighed, sexed and examined for external, visceral and skeletal malformations and
developmental variations.
All females survived to the scheduled necropsy on gestation day 21. No test article-related clinical
or macroscopic ﬁndings were noted at any dosage level. Mean body weights, body weight gains,
gravid uterine weights and food consumption were unaffected by test article administration at all
dosage levels. No test article-related ﬁndings were noted on intrauterine growth and survival and fetal
morphology at any dosage level. The mean litter proportion (per cent per litter) of late resorptions in
the 500 mg/kg per day group (2.8% per litter) was above the maximum mean value in the
laboratories historical control data (0.5% per litter); however, this did not occur in a dose-related
manner, the value was primarily due to 1 litter with 64% late resorptions. The difference from the
concurrent control group was not statistically signiﬁcant.
Based on the lack of test article-related effects at any dosage level, a dosage level of 1,000 mg/kg
per day, the highest dosage level evaluated, was considered to be the NOAEL for maternal toxicity and
embryo/fetal development effects when the candidate substance was administered orally by gavage to
inbred Crl:CD(SD) rats (Table E.1).
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